Fate Therapeutics registers Phase 1/2 trial of FT839 across five autoimmune diseases
The trial, listed September 2, 2026, tests the allogeneic CD19/CD38-targeted cell therapy alone or with rituximab in an open-label design.
Fate Therapeutics posted one new registry entry this week covering its FT839 program.
- FT839, described in the record as allogeneic T cells targeting CD19 and CD381, is entering an open-label Phase 1/2 trial that is recruiting as of the September 2, 2026 posting date. The study will enroll an estimated 446 participants and covers five conditions: ANCA-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc)1. The Phase 1 portion aims to find the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839, tested alone or together with rituximab, background therapy, or conditioning therapy1, before Phase 2 evaluates efficacy in disease-specific cohorts.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.